Targeting Guanine Nucleotide Exchange Factors for Novel Cancer Drug Discovery

Overview

Journal Expert Opin Drug Discov

Specialties Chemistry
Pharmacology

Date 2024 Jun 17

PMID 38884380

Authors

Sahar F Bannoura

Husain Yar Khan

Md Hafiz Uddin

Ramzi M Mohammad

Boris C Pasche

Asfar S Azmi

Affiliations

Soon will be listed here.

Abstract

Introduction: Guanine nucleotide exchange factors (GEFs) regulate the activation of small GTPases (G proteins) of the Ras superfamily proteins controlling cellular functions. Ras superfamily proteins act as 'molecular switches' that are turned 'ON' by guanine exchange. There are five major groups of Ras family GTPases: Ras, Ran, Rho, Rab and Arf, with a variety of different GEFs regulating their GTP loading. GEFs have been implicated in various diseases including cancer. This makes GEFs attractive targets to modulate signaling networks controlled by small GTPases.

Areas Covered: In this review, the roles and mechanisms of GEFs in malignancy are outlined. The mechanism of guanine exchange activity by GEFs on a small GTPase is illustrated. Then, some examples of GEFs that are significant in cancer are presented with a discussion on recent progress in therapeutic targeting efforts using a variety of approaches.

Expert Opinion: Recently, GEFs have emerged as potential therapeutic targets for novel cancer drug development. Targeting small GTPases is challenging; thus, targeting their activation by GEFs is a promising strategy. Most GEF-targeted drugs are still in preclinical development. A deeper biological understanding of the underlying mechanisms of GEF activity and utilizing advanced technology are necessary to enhance drug discovery for GEFs in cancer.

References

Hetzer M, Walther T, Gruss O, Mattaj I . GTP hydrolysis by Ran is required for nuclear envelope assembly. Mol Cell. 2000; 5(6):1013-24. DOI: 10.1016/s1097-2765(00)80266-x. View

Maldonado M, Medina J, Velazquez L, Dharmawardhane S . Targeting Rac and Cdc42 GEFs in Metastatic Cancer. Front Cell Dev Biol. 2020; 8:201. PMC: 7156542. DOI: 10.3389/fcell.2020.00201. View

Karlsson R, Pedersen E, Wang Z, Brakebusch C . Rho GTPase function in tumorigenesis. Biochim Biophys Acta. 2009; 1796(2):91-8. DOI: 10.1016/j.bbcan.2009.03.003. View

Maldonado M, Dharmawardhane S . Targeting Rac and Cdc42 GTPases in Cancer. Cancer Res. 2018; 78(12):3101-3111. PMC: 6004249. DOI: 10.1158/0008-5472.CAN-18-0619. View

Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B . Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer. 2002; 87(6):635-44. PMC: 2364248. DOI: 10.1038/sj.bjc.6600510. View

Cai D, Choi P, Gelbard M, Meyerson M . Identification and Characterization of Oncogenic Mutations in Lung Adenocarcinoma. Mol Cancer Res. 2019; 17(4):1002-1012. PMC: 6445719. DOI: 10.1158/1541-7786.MCR-18-0316. View

Vetter I, Wittinghofer A . The guanine nucleotide-binding switch in three dimensions. Science. 2001; 294(5545):1299-304. DOI: 10.1126/science.1062023. View

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

Yuan Y, Zhang H, Li D, Li Y, Lin F, Wang Y . PAK4 in cancer development: Emerging player and therapeutic opportunities. Cancer Lett. 2022; 545:215813. DOI: 10.1016/j.canlet.2022.215813. View

10.

Depeille P, Henricks L, van de Ven R, Lemmens E, Wang C, Matli M . RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat Cell Biol. 2015; 17(6):804-15. PMC: 4652934. DOI: 10.1038/ncb3175. View

11.

Stengel K, Zheng Y . Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signal. 2011; 23(9):1415-23. PMC: 3115433. DOI: 10.1016/j.cellsig.2011.04.001. View

12.

Weizhong Z, Shuohui G, Hanjiao Q, Yuhong M, Xiaohua Y, Jian C . Inhibition of cytohesin-1 by siRNA leads to reduced IGFR signaling in prostate cancer. Braz J Med Biol Res. 2011; 44(7):642-6. DOI: 10.1590/s0100-879x2011007500072. View

13.

Sandilands E, Freckmann E, Cumming E, Roman-Fernandez A, McGarry L, Anand J . The small GTPase ARF3 controls invasion modality and metastasis by regulating N-cadherin levels. J Cell Biol. 2023; 222(4). PMC: 9997661. DOI: 10.1083/jcb.202206115. View

14.

Erasmus J, Smolarczyk K, Brezovjakova H, Mohd-Naim N, Lozano E, Matter K . Rac1-PAK1 regulation of Rab11 cycling promotes junction destabilization. J Cell Biol. 2021; 220(6). PMC: 8091128. DOI: 10.1083/jcb.202002114. View

15.

Izaurralde E, Kutay U, von Kobbe C, Mattaj I, Gorlich D . The asymmetric distribution of the constituents of the Ran system is essential for transport into and out of the nucleus. EMBO J. 1997; 16(21):6535-47. PMC: 1170258. DOI: 10.1093/emboj/16.21.6535. View

16.

Casanova J . Regulation of Arf activation: the Sec7 family of guanine nucleotide exchange factors. Traffic. 2007; 8(11):1476-85. DOI: 10.1111/j.1600-0854.2007.00634.x. View

17.

Haggag Y, Ras B, El-Tanani Y, Tambuwala M, McCarron P, Isreb M . Co-delivery of a RanGTP inhibitory peptide and doxorubicin using dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer cells. Expert Opin Drug Deliv. 2020; 17(11):1655-1669. DOI: 10.1080/17425247.2020.1813714. View

18.

Gu S, Hou Y, Dovat K, Dovat S, Song C, Ge Z . Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia. Exp Hematol Oncol. 2023; 12(1):23. PMC: 9972767. DOI: 10.1186/s40164-023-00383-5. View

19.

Bischoff F, Ponstingl H . Catalysis of guanine nucleotide exchange on Ran by the mitotic regulator RCC1. Nature. 1991; 354(6348):80-2. DOI: 10.1038/354080a0. View

20.

Vigil D, Cherfils J, Rossman K, Der C . Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. Nat Rev Cancer. 2010; 10(12):842-57. PMC: 3124093. DOI: 10.1038/nrc2960. View